



AMERICAN  
COLLEGE of  
CARDIOLOGY®

# ALPACAR-360

Zerlasiran – A Small-Interfering RNA  
Targeting Lipoprotein(a)

## OBJECTIVE

Evaluate the effects of zerlasiran on LP(a) serum concentration

## STUDY METHODS

**TOTAL NO. OF PATIENTS: 178**  
(26 sites in 7 countries)

**INCLUSION CRITERIA:**  
Adults with atherosclerotic cardiovascular disease (ASCVD)  
median baseline Lp(a) 213 nmol/L

**STUDY DESIGN:**  
Randomized 1:1:2:2:2 to receive subcutaneous:  
  
Placebo every 16 weeks for 3 doses or  
every 24 weeks for 2 doses  
  
Zerlasiran 450 mg every 24 weeks for 2 doses,  
300 mg every 16 weeks for 3 doses or  
300 mg every 24 weeks for 2 doses

## PRIMARY ENDPOINTS

**FOR THE PRIMARY ENDPOINT, TIME-AVERAGED REDUCTION  
IN LP(a) DURING 36 WEEKS OF FOLLOW-UP, ALL THREE  
REGIMENS PRODUCED AN 80% OR GREATER REDUCTION  
COMPARED WITH PLACEBO.**

## CONCLUSION

Zerlasiran was well-tolerated and reduced time-averaged Lp(a) concentration by >80% during 36 weeks of treatment in patients with ASCVD, with no safety concerns.